Home › Heart Failure › Indiana › Richmond
Heart Failure clinical trials in Richmond, IN
6 studies for Heart Failure are looking for participants at sites in and around Richmond (within about 30 miles). Open a study to see who can join and how to contact the study team.
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RecruitingPhase 3
- Reid Physician Associates, Richmond
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
RecruitingPhase 3
- Reid Hospital, Richmond
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RecruitingPhase 3
- Reid Hospital, Richmond
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
RecruitingPhase 3
- Reid Physician Associates, Richmond
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
RecruitingPhase 3
- Research Site, Richmond
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RecruitingPhase 2
- Reid Physician Associates, Richmond
About Heart Failure
Heart failure, or congestive heart failure (CHF), means the heart can't pump enough blood. Learn about the signs, symptoms, and causes.
More about Heart Failure on MedlinePlus
Heart Failure trials in other cities
- New York City, NY50 studies
- Boston, MA43 studies
- Dallas, TX42 studies
- Houston, TX36 studies
- Cleveland, OH33 studies
- Chicago, IL32 studies
- Philadelphia, PA31 studies
- San Francisco, CA29 studies
- Durham, NC26 studies
- St. Louis, MO26 studies
- Kansas City, MO25 studies
- Atlanta, GA25 studies
Other studies in Richmond
- Cardiovascular Disease3 studies
- Breast Cancer3 studies
- Colorectal Cancer3 studies
- Melanoma3 studies
- Prostate Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.